Substituted spiroheterocycles
    1.
    发明授权
    Substituted spiroheterocycles 有权
    取代螺旋环

    公开(公告)号:US07825111B2

    公开(公告)日:2010-11-02

    申请号:US11857954

    申请日:2007-09-19

    IPC分类号: A61P9/00 A61K31/55 C07D223/14

    CPC分类号: C07D487/10

    摘要: The invention is directed to nonpeptide substituted spiroheterobenzazepine of Formula I, which are useful as vasopressin receptor antagonists for treating conditions associated with vasopressin receptor activity such as those involving increased vascular resistance and cardiac insufficiency, including congestive heart failure, hyponatremia, and hypertension. Pharmaceutical compositions comprising a compound of Formula I and methods of treating conditions such as hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, hyponatremia, renal vasospasm, renal failure, diabetic nephropathy, cerebral edema, cerebral ischemia, stroke, thrombosis, or water retention are also disclosed.

    摘要翻译: 本发明涉及式I的非肽取代的螺杂肼苯并氮平,其可用作加压素受体拮抗剂,用于治疗与加压素受体活性相关的病症,例如涉及增加的血管阻力和心脏功能不全(包括充血性心力衰竭,低钠血症和高血压)的那些。 包含式I化合物的药物组合物和治疗诸如高血压,充血性心力衰竭,心脏功能不全,冠状动脉血管痉挛,心脏缺血,肝硬化,低钠血症,肾血管痉挛,肾衰竭,糖尿病性肾病,脑水肿,脑缺血, 中风,血栓形成或保水性也被公开。

    Substituted spiroheterocycles
    2.
    发明授权
    Substituted spiroheterocycles 有权
    取代螺旋环

    公开(公告)号:US07825110B2

    公开(公告)日:2010-11-02

    申请号:US11857891

    申请日:2007-09-19

    IPC分类号: A61P9/00 A61K31/55 C07D223/14

    CPC分类号: C07D487/10

    摘要: The invention is directed to nonpeptide substituted spiroheterobenzazepine of Formula I, which are useful as vasopressin receptor antagonists for treating conditions associated with vasopressin receptor activity such as those involving increased vascular resistance and cardiac insufficiency, including congestive heart failure, hyponatremia, and hypertension. Pharmaceutical compositions comprising a compound of Formula I and methods of treating conditions such as hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, hyponatremia, renal vasospasm, renal insufficiency, renal failure, diabetic nephropathy, cerebral edema, cerebral ischemia, stroke, thrombosis, or water retention are also disclosed.

    摘要翻译: 本发明涉及式I的非肽取代的螺杂肼苯并氮平,其可用作加压素受体拮抗剂,用于治疗与加压素受体活性相关的病症,例如涉及增加的血管阻力和心脏功能不全(包括充血性心力衰竭,低钠血症和高血压)的那些。 包含式I化合物的药物组合物和治疗诸如高血压,充血性心力衰竭,心脏功能不全,冠状动脉血管痉挛,心脏缺血,肝硬化,低钠血症,肾血管痉挛,肾功能不全,肾衰竭,糖尿病性肾病,脑水肿, 还公开了脑缺血,中风,血栓形成或保水。

    SUBSTITUTED SPIROHETEROCYCLES
    3.
    发明申请
    SUBSTITUTED SPIROHETEROCYCLES 有权
    取代的螺旋体

    公开(公告)号:US20080076753A1

    公开(公告)日:2008-03-27

    申请号:US11857891

    申请日:2007-09-19

    CPC分类号: C07D487/10

    摘要: The invention is directed to nonpeptide substituted spiroheterobenzazepine of Formula I, which are useful as vasopressin receptor antagonists for treating conditions associated with vasopressin receptor activity such as those involving increased vascular resistance and cardiac insufficiency, including congestive heart failure, hyponatremia, and hypertension. Pharmaceutical compositions comprising a compound of Formula I and methods of treating conditions such as hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, hyponatremia, renal vasospasm, renal insufficiency, renal failure, diabetic nephropathy, cerebral edema, cerebral ischemia, stroke, thrombosis, or water retention are also disclosed.

    摘要翻译: 本发明涉及式I的非肽取代的螺杂肼苯并氮平,其可用作加压素受体拮抗剂,用于治疗与加压素受体活性相关的病症,例如涉及增加的血管阻力和心脏功能不全(包括充血性心力衰竭,低钠血症和高血压)的那些。 包含式I化合物的药物组合物和治疗诸如高血压,充血性心力衰竭,心脏功能不全,冠状动脉血管痉挛,心脏缺血,肝硬化,低钠血症,肾血管痉挛,肾功能不全,肾衰竭,糖尿病性肾病,脑水肿, 还公开了脑缺血,中风,血栓形成或保水。

    SUBSTITUTED SPIROHETEROCYCLES
    4.
    发明申请
    SUBSTITUTED SPIROHETEROCYCLES 有权
    取代的螺旋体

    公开(公告)号:US20080076754A1

    公开(公告)日:2008-03-27

    申请号:US11857954

    申请日:2007-09-19

    CPC分类号: C07D487/10

    摘要: The invention is directed to nonpeptide substituted spiroheterobenzazepine of Formula I, which are useful as vasopressin receptor antagonists for treating conditions associated with vasopressin receptor activity such as those involving increased vascular resistance and cardiac insufficiency, including congestive heart failure, hyponatremia, and hypertension. Pharmaceutical compositions comprising a compound of Formula I and methods of treating conditions such as hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, hyponatremia, renal vasospasm, renal failure, diabetic nephropathy, cerebral edema, cerebral ischemia, stroke, thrombosis, or water retention are also disclosed.

    摘要翻译: 本发明涉及式I的非肽取代的螺杂肼苯并氮平,其可用作加压素受体拮抗剂,用于治疗与加压素受体活性相关的病症,例如涉及增加的血管阻力和心脏功能不全(包括充血性心力衰竭,低钠血症和高血压)的那些。 包含式I化合物的药物组合物和治疗诸如高血压,充血性心力衰竭,心脏功能不全,冠状动脉血管痉挛,心脏缺血,肝硬化,低钠血症,肾血管痉挛,肾衰竭,糖尿病性肾病,脑水肿,脑缺血, 中风,血栓形成或保水性也被公开。

    GPR40 agonists
    5.
    发明授权
    GPR40 agonists 有权
    GPR40激动剂

    公开(公告)号:US07750048B2

    公开(公告)日:2010-07-06

    申请号:US11939039

    申请日:2007-11-13

    IPC分类号: A61K31/192 C07C59/64

    摘要: The invention is directed to compounds of Formula (I) useful as GPR40 agonists. Pharmaceutical compositions and methods of treating one or more conditions including, but not limited to, insulin resistance, hyperglycemia, obesity, diabetes such as NIDDM, and other disorders related to lipid metabolism, energy homeostasis, and complications thereof, using compounds of the invention are also described.

    摘要翻译: 本发明涉及用作GPR40激动剂的式(I)化合物。 使用本发明化合物治疗一种或多种病症的药物组合物和方法,包括但不限于胰岛素抵抗,高血糖症,肥胖症,糖尿病如NIDDM,以及与脂质代谢相关的其它障碍,能量稳态及其并发症, 也描述。